Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period of time. This trial is evaluating if shorter duration radiation prevents cancer from coming back as well as the usual radiation treatment.

Trial Details

NCT ID

NCT05946213

Phase

PHASE3

Sponsor

NRG Oncology

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

Biospecimen Collection
Bone Scan
Computed Tomography
External Beam Radiation Therapy
Magnetic Resonance Imaging
Positron Emission Tomography

Locations (sample)

Birmingham, Alabama, United States|33.52066,-86.80249
Birmingham, Alabama, United States|33.52066,-86.80249
Tuscaloosa, Alabama, United States|33.20984,-87.56917
Little Rock, Arkansas, United States|34.74648,-92.28959
Antioch, California, United States|38.00492,-121.80579

Key Eligibility Criteria

Pathologically (histologically or cytologically) proven diagnosis of adenocarcinoma of prostate cancer
High-risk disease defined as having at least one or more of the following:
cT3a-T3b by digital exam or imaging (American Joint Committee on Cancer \[AJCC\] 8th edition \[Ed.\]) Note: cT4 by imaging or on digital rectal exa…
The patient's prostate specific antigen (PSA) value \> 20 ng/mL prior to starting androgen deprivation therapy (ADT) Note: Patients taking a 5-alph…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →